检测肝细胞癌中 p16 蛋白衍生肽的循环抗体。

Detection of Circulating Antibodies to p16 Protein-Derived Peptides in Hepatocellular Carcinoma.

机构信息

Second Hospital of Jilin University, Changchun, China.

Department of Hepatobiliary & Pancreatic Surgery, Jilin Province People's Hospital, Changchun, China.

出版信息

Lab Med. 2020 Nov 2;51(6):574-578. doi: 10.1093/labmed/lmaa006.

DOI:10.1093/labmed/lmaa006

PMID:32195537

Abstract

OBJECTIVE

This study aimed at confirming the alteration of circulating anti-p16 immunoglobulin G (IgG) levels in hepatocellular carcinoma (HCC).

METHODS

An in-house-developed enzyme-linked immunosorbent assay was used for determining plasma IgG antibodies against p16-derived antigens in 122 HCC patients and 134 healthy controls.

RESULTS

Plasma anti-p16 IgG levels were significantly higher in HCC patients than in the controls (Z = 3.51, P = 0.0004), with no difference between males and females. A trend of increasing plasma anti-p16 IgG levels was associated with increasing HCC stage, with group 3 patients having the highest anti-p16 IgG levels (Z = 3.38, P = 0.0008). Group 3 exhibited the best sensitivity (19.6%) and specificity (95%) for plasma anti-p16 IgG detection, with an area under the receiver operating characteristic curve of 0.659 (95% confidence interval, 0.564-0.754).

CONCLUSION

Circulating IgG antibody to p16 protein might be a useful biomarker for HCC prognosis assessment rather than for early malignancy diagnosis.

摘要

目的

本研究旨在证实循环抗 p16 免疫球蛋白 G（IgG）水平在肝细胞癌（HCC）中的变化。

方法

采用内部开发的酶联免疫吸附试验，测定 122 例 HCC 患者和 134 例健康对照者血浆中针对 p16 衍生抗原的 IgG 抗体。

结果

HCC 患者的血浆抗 p16 IgG 水平明显高于对照组（Z=3.51，P=0.0004），且男女之间无差异。血浆抗 p16 IgG 水平与 HCC 分期呈递增趋势，其中第 3 组患者的抗 p16 IgG 水平最高（Z=3.38，P=0.0008）。第 3 组对血浆抗 p16 IgG 的检测具有最佳的灵敏度（19.6%）和特异性（95%），受试者工作特征曲线下面积为 0.659（95%置信区间，0.564-0.754）。